Want to join the conversation?
Jeff Holford with Jefferies asks about the ACV franchise, the ex-US sales over the next few quarters. $BMY said it has seen the maturation of its business in Japan. New competitive entrants have significantly reduced $BMY's performance there. In Europe, the company continues to sustain a very high penetration of the genotype 3 patient population.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?